FLT4 and hyperphosphatemia: Considering that the hyperphosphatemia is a common metabolic disorder for pre‐dialysis CKD patients, this study provides a novel immunoregulation strategy for AVFs under CKD condition, as suppressing BACE2‐mediated VEGFR3 cleavage to recover a functionally competent lymphatic network is a potential target.